🇺🇸 FDA

Intelligence Platform

Patents

Browse 912 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12310992

Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progeni

United Therapeutics Corporation · Granted Tue May 27 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12310986

Compositions and methods for the treatment of cancer cells by induction of cytotoxic oxida

The Board of Regents of the University of Texas System · Granted Tue May 27 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12304968

T-cells expressing anti-LIV1 chimeric antigen receptor

CRISPR THERAPEUTICS AG · Granted Tue May 20 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 15 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12297452

Methods or generating T-cells from stem cells and immunotherapeutic methods using the T-ce

The Regents of the University of California · Granted Tue May 13 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 08 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12274684

Treatment of vasculopathy with prostacyclin and mesenchymal stem cells

United Therapeutics Corporation · Granted Tue Apr 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12275966

Genetically engineered cells

The Regents of the University of California · Granted Tue Apr 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12268700

3-o-sulfo-galactosylceramide analogs as activators of type II NKT cells and uses thereof

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12263165

Small molecule inhibitors of cancer stem cells and mesenchymal cancer types

The Board of Regents of the University of Texas System · Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12264322

Minimal volume reprogramming of mononuclear cells

Fate Therapeutics, Inc. · Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12251403

Genetically engineered hematopoietic stem cells and uses thereof

Vor Biopharma Inc. · Granted Tue Mar 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12241087

Compositions and methods for differentiating stem cells into NK cells

CRISPR THERAPEUTICS AG · Granted Tue Mar 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12234480

Therapeutic methods involving modulating inflammasome activation of myeloid-derived suppre

Regents of the University of Minnesota · Granted Tue Feb 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12230379

Systems and methods for coordinating manufacturing of cells for patient-specific immunothe

Iovance Biotherapeutics, Inc. · Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12230378

Systems and methods for coordinating manufacturing of cells for patient-specific immunothe

Iovance Biotherapeutics, Inc. · Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12227554

Methods for selectively expanding cells expressing a TCR with a murine constant region

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12228572

Enhanced expression of polo-like kinase 3 (PLK3) in human immunodeficiency virus (HIV)-inf

The First Hospital of China Medical University · Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12221627

Methods of enriching cell populations for cancer-specific T cells using in vitro stimulati

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12221622

Modified pluripotent cells

The Regents of the University of California · Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12221462

Methods and compositions for dosing of allogeneic chimeric antigen receptor T cells

Allogene Therapeutics, Inc. · Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12221629

Methods for producing fibroadipogenic progenitor cells

Regents of the University of Minnesota · Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12215349

Methods of preparing an isolated or purified population of thymic emigrant cells and metho

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12215162

BAFF-R targeted chimeric antigen receptor-modified T-cells and uses thereof

The Board of Regents of the University of Texas System · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12213998

Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal

Takeda Pharmaceutical Company Limited · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12209255

Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses ther

Astellas Institute for Regenerative Medicine · Granted Tue Jan 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted